The Board of Pharmacy has received notice of the following product recall. The Board strongly encourages pharmacies to immediately review their quality assurance and recall policies and procedures to determine if any corrective action is required.

Imprimis NJOF is issuing a recall for Prednisolone-Moxifloxacin-Bromfenac (1%, 5%, 0.075%) Sterile Ophthalmic Suspension. During a recent FDA inspection, investigators observed instances where an internal standard operating procedure regarding filter integrity testing was not followed by Imprimis NJOF ("Imprimis").

Imprimis' assessment of this issue revealed the "likelihood of a health hazard is unlikely", however, out of an abundance of caution, Imprimis NJOF ("Imprimis") has initiated a voluntary recall of all unexpired lots that reflect this internal deviation from procedure.

This lot obtained passing results for sterility, potency, endotoxin testing (where applicable), identification, minimum fill, finished product pH, and description/color/clarity testing prior to release. Additionally, this lot was fully reviewed and dispositioned by members of the Quality Assurance department before release. Furthermore, no adverse drug events were reported for this lot.

Product Name: Prednisolone-Moxifloxacin-Bromfenac (1%, 5%, 0.075%) Sterile Ophthalmic Suspension

Description: Multiuse Sterile Topical Ophthalmic Suspension

NDC: 71384-310-05

Lot Numbers:

Product	Lot Number	Date Compounded	Expiry Date	Distribution Date Ranges	
PMB Suspension	23NOV018	11/21/23	6/17/2024	1/4/2024	1/10/2024